Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with 'wearing-off' phenomenon: A multicentre, double-blind, randomized, placebo-controlled trial

European Journal of Neurology

Volumn 4, Issue 4, 1997, Pages 333-341

  Myllyla V V ^a   Jackson, M ^b   Larsen, J P ^c   Baas, H ^d  

^a UNIVERSITY OF OULU   (Finland)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

'Wearing off' phenomenon; Levodopa therapy; Motor fluctuations; Parkinson's disease; Tolcapone

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; TOLCAPONE;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSTONIA; FEMALE; HALLUCINATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP DISORDER; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA;

EID: 0030700836     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1997.tb00358.x     Document Type: Article

References (28)

1. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Schläppi B and Zürcher G (1991) Ro 40-7592: catecholamine-O-methyltransferase (COMT) inhibitor. Drugs of the Future, 16, 719-721.
2. Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clinical Pharmacokinetics, 13, 141-178.
3. Chase TN, Engber TM and Mouradian MM (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology, 44 (Suppl. 6), S15-S18.
4. Cotzias GC, Van Woert MH and Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine, 276, 374-379.
5. Da Prada M (1991) New approaches to the treatment of age-related brain disorders. Canadian Journal of Neurological Sciences, 18, 384-386.
6. Da Prada M, Keller HH, Pieri L, Kettler R and Haefely WE. (1984) The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia, 40, 1165-1172.
7. Davis TL, Roznoski M and Burns RS (1995) Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clinical Neuropharmacology, 18, 333-337.
8. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M and van Brummelen P (1995a) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. British Journal of Clinical Pharmacology, 40, 253-262.
9. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M and van Brummelen P (1995b) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clinical Pharmacology and Therapeutics, 57, 508-517.
10. Fahn S (1989) Adverse effects of levodopa in Parkinson's disease. In: Drugs for the Treatment of Parkinson's Disease (Ed. DB Calne), pp. 385-409. Berlin, Springer.
11. Hauser RA and Olanow CW (1992) Designing Clinical Trials in Parkinson's Disease. In: The Scientific Basis for the Treatment oj Parkinson's Disease (Eds CW Olanow, AN Lieberman), pp. 275-293. Carnforth, Parthenon Publishing Group.
12. Hornykiewicz O (1982) Brain neurotransmitter changes in Parkinson's disease. In: Movement Disorders (Eds CD Marsden, S Fahn), pp. 41-58. London, Butterworth Scientific.
13. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Schultz E, Seppälä L and Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administrations of entacapone. European Journal of Clinical Pharmacology, 46, 151-157.
14. Kish SJ, Shannak K and Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. New England Journal of Medicine, 318, 876-880.
15. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R and Perret JE (1995) Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clinical Neuropharmacology, 18, 258-265.
16. Lloyd KG, Davidson L and Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: effect of L-DOPA therapy. Journal of Pharmacology and Experimental Therapeutics, 195, 453-464.
17. Männistö PT (1994) Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs, 1, 172-179.
18. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C and Kaakkola S (1992) Characteristics of catechol-O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Progress in Drug Research, 39, 291-350.
19. Marsden CD (1994) Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 57, 672-681.
20. Mouradian MM, Heuser IJE, Baronti F and Chase TN (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology, 27, 18-23.
21. Muenter M, Dinapoli R, Sharpless N and Tyce G (1973) 3-O-Methyldopa, L-dopa and trihexylphenidyl in the treatment of Parkinson's disease. Mayo Clinic Proceedings, 48, 173-183.
22. Nutt JG (1987) On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Annals of Neurology, 22, 535-540.
23. Quinn N, Parkes JD and Marsden CD (1984) Control of on/ off phenomenon by continuous intravenous infusion of levodopa. Neurology, 34, 1131-1136.
24. Rinne UK (1983) Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurologica Scandinavica Supplement, 95, 19-26.
25. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM and Chase TN (1993) Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology, 43, 2685-2688.
26. Wade LA and Katzman R (1975) 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sciences, 17, 131-136.
27. Zürcher G, Colzi A and Da Prada M (1990) Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. Journal of Neural Transmission. Supplementum (Wien), 32, 375-380.
28. Zürcher G, Dingemanse J and Da Prada M (1991) Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: New Developments in Therapy of Parkinson's Disease (Eds A Agnoli, G Campanella), pp. 37-43. Rome, Italy, John Libbey.